The COVID-19 pandemic has required an unprecedented public health response, with governments dedicating massive amounts of resources to their health systems at extraordinary speed. Governments have had to respond quickly to fast-changing contexts, with many competing interests, and little in the way of historical precedent to guide them.
This report explores why and how a company ought to measure the effectiveness of its approach to anti-corruption. We analyse what is understood by “measuring effectiveness”, highlight practical considerations, and provide examples of metrics that are proving useful for companies.
The COVID-19 pandemic has required a rapid public health response on a scale and speed unseen in modern times. Whilst those procuring goods and services have sought to expedite the emergency response, we observe a pattern of behaviour whereby critical safeguards for protecting the public purse have been thrown aside without adequate justification.
Emerging evidence from investigative journalists, the National Audit Office (NAO) and public interest litigation highlights these in startling detail.
